Comparison | Global Evaluation of Change | Treatment | N | Mean | 95% Lower CI | 95% Upper CI |
---|---|---|---|---|---|---|
Baseline to Week 12 | No change | Adalimumab | 28 | 1.3 | −0.24 | 2.77 |
Placebo | 25 | 0.5 | 0.16 | 0.88 | ||
Change | Adalimumab | 6 | 14.5 | 8.06 | 20.94 | |
Placebo | 9 | 7.3 | 3.64 | 11.03 | ||
Baseline to Week 52 | No change | Adalimumab | 26 | 1.2 | −0.37 | 2.75 |
Placebo | 24 | 1.4 | −0.09 | 2.88 | ||
Change | Adalimumab | 3 | 14.5 | 0.50 | 28.50 | |
Placebo | 8 | 13.9 | 8.02 | 19.85 | ||
Week 12 to Week 52 | No change | Adalimumab | 27 | 0.2 | 0.07 | 0.41 |
Placebo | 24 | 1.9 | 0.18 | 3.57 | ||
Change | Adalimumab | 4 | 2.9 | 0.02 | 5.73 | |
Placebo | 10 | 11.3 | 6.28 | 16.22 | ||
All visits | No change | Adalimumab | 81 | 0.9 | 0.20 | 1.60 |
Placebo | 73 | 1.3 | 0.53 | 1.98 | ||
Change | Adalimumab | 13 | 10.9 | 6.52 | 15.32 | |
Placebo | 27 | 10.7 | 8.10 | 13.38 |
SPARCC: SpondyloArthritis Research Consortium of Canada.